<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653574</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2012-10</org_study_id>
    <nct_id>NCT01653574</nct_id>
  </id_info>
  <brief_title>A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer</brief_title>
  <official_title>A Single-Institutional, Phase II, Open-label, Single Arm Trial of Famitinib Malate in in HER2-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this clinical research study is to discover if the study drug Famitinib&#xD;
      Malate can shrink or slow the growth of pretreated HER2-negative metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Famitinib Malate is a tyrosine kinase inhibitor mainly targeting vascular endothelial growth&#xD;
      factor receptor 2(VEGFR2), and its anti-angiogenesis effect has been viewed in preclinical&#xD;
      tests. The investigators' phase I study has shown that the drug's toxicity is manageable and&#xD;
      the recommended phase II dose is 25 mg. The hypothesis of this clinical research study is to&#xD;
      discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated&#xD;
      HER2-negative breast cancer. The safety of Famitinib Malate will also be studied. Patients&#xD;
      physical state, symptoms, changes in the size of the tumor, and laboratory findings obtained&#xD;
      while on-study will help the research team decide if Famitinib Malate is safe and effective&#xD;
      in pretreated HER2-negative metastatic breast cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (Objective response rate)</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS(Progression free survival)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall survival)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR(Clinical benefit rate)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL (Quality of life)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Famitinib Malate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Famitinib 25mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib Malate</intervention_name>
    <description>The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.</description>
    <arm_group_label>Famitinib Malate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ●≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Women diagnosed with HER2-negative breast cancer. HER2- is defined as 0 or 1+ staining&#xD;
             on immunohistochemistry or FISH/CISH negative for gene amplification.&#xD;
&#xD;
          -  Metastatic breast cancer, confirmed by histological analysis.&#xD;
&#xD;
          -  Have failed from the last chemotherapy regimen, but experienced at most 2 regimens in&#xD;
             the relapsed or metastatic setting. Pretreated anthracycline, taxanes and capecitabine&#xD;
             (any rational reason for no use of capecitabine is acceptable) are mandatory.&#xD;
&#xD;
          -  Have failed from at least 1 endocrine therapy, if HR positive.&#xD;
&#xD;
          -  Duration from the last therapy (chemotherapy, radiotherapy, target therapy and&#xD;
             operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).&#xD;
&#xD;
          -  Have at least one extracranial measurable site of disease according to RECIST 1.1&#xD;
             criteria that has not been previously irradiated.&#xD;
&#xD;
          -  Life expectancy of more than 3 months.&#xD;
&#xD;
          -  If the patients have brain or meninges metastases, the lesions must have been&#xD;
             controlled at least 8 weeks.&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L,&#xD;
             neutrophils ≥ 1.5×10^9/L, platelets ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit of normal&#xD;
             (ULN), AST ≤ 2.5 x ULN, serum bilirubin ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN,&#xD;
             creatinine clearance rate ≥ 50ml/min, PT, APTT ≤ 1.5 x ULN), serum cholesterol ≤ 1.25&#xD;
             x ULN, serum glycerin trilaurate ≤ 2.0 x ULN, LVEF ≥ lower limit of normal (LLN).&#xD;
&#xD;
          -  Negative serum or urine pregnancy test taken in all women within 7 days before&#xD;
             inclusion. Sexually active women of childbearing potential must use a medically&#xD;
             acceptable form of contraception (which include oral contraception, injectable or&#xD;
             implantable methods, intrauterine devices, or properly used barrier contraception)&#xD;
             from the beginning of the study to 8 weeks after the last dose of the investigated&#xD;
             drug. A woman of childbearing potential is defined as one who is biologically capable&#xD;
             of becoming pregnant. This includes women who are using contraceptives or whose sexual&#xD;
             partners are either sterile or using contraceptives.&#xD;
&#xD;
          -  Written informed consent prior to study specific screening procedures, with the&#xD;
             understanding that the patient has the right to withdraw from the study at any time&#xD;
             without prejudice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Uncontrolled hypertension with mono-drug therapy (&gt;140/90 mm Hg)；ischemia of the&#xD;
             myocardium （≥ grade 2） or myocardial infarction；arrhythmia（≥ grade 2, QTcF &gt; 480ms for&#xD;
             female patients） or New York Heart Association Class III/IV.&#xD;
&#xD;
          -  Abnormal thyroid function history with drug intervention.&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration.&#xD;
&#xD;
          -  The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 300&#xD;
             mg/m2 and 600 mg/m2, respectively.&#xD;
&#xD;
          -  Brain or meningeal metastases.&#xD;
&#xD;
          -  Receiving the therapy of thrombolysis or anticoagulation.&#xD;
&#xD;
          -  Unhealed wound or bone fracture.&#xD;
&#xD;
          -  Urine protein ≥++ and confirmed &gt;1.0 g by the 24h quantity.&#xD;
&#xD;
          -  Previous or present history of pulmonary fibrosis,interstitial pneumonia,&#xD;
             pneumoconiosis, radiation pneumonitis, drug-related pneumonitis or greatly-impaired&#xD;
             pulmonary function.&#xD;
&#xD;
          -  Disability of serious uncontrolled intercurrence infection.&#xD;
&#xD;
          -  The active HBV or HCV infection or HBV DNA ≥10^4/ml.&#xD;
&#xD;
          -  Acquired or inherent immunodeficiency； HIV infection； organ transplantation history.&#xD;
&#xD;
          -  Abuse of alcohol or drugs.&#xD;
&#xD;
          -  Have received prior treatment with a VEGFR TKI (Bevacizumab is permitted).&#xD;
&#xD;
          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             in-situ of uterine cervix.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi-Chun Hu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan Univeristy Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>December 1, 2013</last_update_submitted>
  <last_update_submitted_qc>December 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Deputy director of department of medical oncology</investigator_title>
  </responsible_party>
  <keyword>Famitinib Malate</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>HER-2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

